Ruth Lopert
Ruth Lopert
2006-07 Harkness Fellow
Principal Adviser in the Pharmaceutical Policy Taskforce
Commonwealth Department of Health and Ageing in Canberra
View Fellows

Harkness Project Title: Comparing Cost, Coverage, and Access to Pharmaceuticals Under Australian and United States Policy Frameworks

Mentors: Sara Rosenbaum, J.D., Marilyn Moon, Ph.D., and Bruce Stuart, Ph.D.

Placement: Department of Health Policy, School of Public Health & Health Services, George Washington University

Biography at time of Harkness Fellowship: Ruth Lopert, a 2006–07 Commonwealth Fund Harkness Fellow in Health Care Policy, is a public health physician and pharmacoepidemiologist, and is currently principal adviser in the Pharmaceutical Policy Taskforce in the Commonwealth Department of Health and Ageing in Canberra, Australia. Prior to the establishment of the Taskforce in 2005 Lopert held the position of senior medical adviser in the Pharmaceutical Benefits Branch of the Department, providing clinical and policy advice in relation to the operation of the Pharmaceutical Benefits Scheme (PBS) and acting as an adviser to the Pharmaceutical Benefits Advisory Committee (PBAC). Previously Lopert was a senior lecturer in the Department of Clinical Pharmacology at the University of Newcastle, NSW where she was involved in the clinical and economic evaluation of new drugs proposed for listing on the Australian PBS. She is a member of the WHO Expert Advisory Panel on Drug Policies and Management, and was the primary negotiator of the pharmaceutical provisions of the Australia United States Free Trade Agreement. Lopert has published and presented internationally in pharmacoeconomics and has particular interests in pharmaceutical policy, pharmaceutical IP, drug pricing and access to medicines.

Project: The objectives of Ruth Lopert’s research were to analyze the formulary, coverage, and cost of Medicare Part D drug plans, and compare these to the Australian Pharmaceutical Benefits Scheme.  She interviewed representatives of the top ten Part D providers as well as representatives of the pharmaceutical and health insurance industries, the Centers for Medicare and Medicaid Services (CMS), and the United States Pharmacopeia Inc.  Data on Part D plan prices and characteristics came from CMS; data on the Australian scheme were available online.

Career Activity Since Fellowship

  • Visiting Professor, Department of Health Policy, George Washington University, 2011
  • Principal Medical Adviser, Therapeutic Goods Administration, Australian Department of Health and Ageing, 2008
  • Visiting Associate Professor, Department of Health Policy, George Washington University, 2007

Current Position: Principal Adviser, Therapeutic Goods Administration. (Updated 2/2014)


Selected Publications:

R. Lopert and A. G. Elshaug, "Australia's 'Fourth Hurdle' Drug Review Comparing Costs and Benefits Holds Lessons for the United States," Health Affairs, March 2013 32(4):778–87.

Lopert R, Shoemaker JS, Davidoff A, Shaffer T, Abdulhalim AM, Lloyd J, Stuart B. “Medication adherence and Medicare expenditure among beneficiaries with heart failure.” Am J Manag Care. 2012 Sep;18(9):556-63.

Davidoff A, Lopert R, Stuart B, Shaffer T, Lloyd JT, Shoemaker JS. “Simulated value-based insurance design applied to statin use by Medicare beneficiaries with diabetes.” Value Health. 2012 May;15(3):404-11.

Stuart B, Davidoff A, Lopert R, Shaffer T, Samantha Shoemaker J, Lloyd J. “Does medication adherence lower Medicare spending among beneficiaries with diabetes?” Health Serv Res. 2011 Aug;46(4):1180-99.

Lopert R, Nolan T. “Child influenza vaccination. Panvax febrile reactions not a predictor.” BMJ. 2010 Jul 21;341:c3714.

Lopert R. “Medicines and Markets: the USA and Australia.” Australian Prescriber 2009; 32(4):90-91

Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki PT, Nasser M, and Xerri B. “Comparative-Effectiveness Research and Evidence- Based Health Policy: Experience from Four Countries.” Milbank Quarterly, June 2009; 87(2): 339-367.

Lopert R, Evidence-Based Decision-Making Within Australia's Pharmaceutical Benefits Scheme, The Commonwealth Fund, July 2009.

Morgan S, Lopert R, Greyson D. “Toward a Definition of Pharmaceutical Innovation.” Open Medicine 2008;2(1):E4–7.

Dor A, Burke T, Whittington R, Clark T, Lopert R, Rosenbaum S. Assessing the Effects of Federal Pediatric Drug Safety Policies. (Washington: George Washington University, 2007)

Lopert R, Rosenbaum S. "What is Fair?  Choice, Fairness and Transparency in Access to Prescription Medicines in the United States and Australia," Journal of Law Medicine and Ethics 2007; 35(4):643-656.

Lopert R, Moon M. “Toward A Rational, Value-Based Drug Benefit For Medicare,” Health Affairs 2007; 26(6):1


Forgot Password

An email has been sent to {{email}} with your reset password.

Account was not found. Please go to the login page and enter a new password.

Account was not found. Please try again with a different email address.

There was an error when attempting to send to {{email}}. Please contact an administrator.